{"id":959,"date":"2008-02-01T12:00:00","date_gmt":"2008-02-01T11:00:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2008\/neue-antikoagulanzien"},"modified":"2022-03-17T14:11:20","modified_gmt":"2022-03-17T13:11:20","slug":"neue-antikoagulanzien","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2008\/neue-antikoagulanzien","title":{"rendered":"Neue Antikoagulanzien"},"content":{"rendered":"<p>Zusammenfassung: Die so genannten neuen Antikoagulanzien haben erstaunlich schnell den Weg in aktuelle Behandlungsrichtlinien f\u00fcr das Akute Koronarsyndrom gefunden. F\u00fcr eine Beurteilung des Stellenwerts &#8211; speziell in der Kardiologie &#8211; m\u00fcssen jedoch die Ergebnisse weiterer Phase-III-Studien abgewartet werden. Aber auch dann kann man die Sicherheit noch nicht beurteilen, wie das Beispiel Ximelagatran gezeigt hat. Gegen [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Zusammenfassung: Die so genannten neuen Antikoagulanzien haben erstaunlich schnell den Weg in aktuelle Behandlungsrichtlinien f\u00fcr das Akute Koronarsyndrom gefunden. F\u00fcr eine Beurteilung des Stellenwerts &#8211; speziell in der Kardiologie &#8211; m\u00fcssen jedoch die Ergebnisse weiterer Phase-III-Studien abgewartet werden. Aber auch dann kann man die Sicherheit noch nicht beurteilen, wie das Beispiel Ximelagatran gezeigt hat. Gegen [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[185,2453,2452,684,495,137,1322,2454,184,61,1379,2456,2305,1749,1314,1312,2455,2457,98,99,2458,71,187,687,100,498,1771,65,1328,1327,1787,2450,2451,2449,183,2304,2448,54,51,181,1344],"class_list":["post-959","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-absolute-arrhythmie","tag-acuity-studie","tag-aktiviertes-protein-c","tag-akutes-koronarsyndrom","tag-angina-pectoris","tag-antikoagulanzien","tag-apixaban","tag-argatroban","tag-arrhythmien","tag-beinvenenthrombose","tag-bivalirudin","tag-bivalirudin-angioplasty-study","tag-dabigatran","tag-desirudin","tag-direkte-orale-antikoagulanzien","tag-doak","tag-drotrecogin-alfa","tag-fondaparinux","tag-heparin","tag-heparininduzierte-thrombozytopenie","tag-hero-2-studie","tag-herzinfarkt","tag-herzrhythmusstoerungen","tag-hirudin","tag-hit","tag-koronare-herzkrankheit","tag-lepirudin","tag-myokardinfarkt","tag-neue-orale-antikoagulanzien","tag-noak","tag-oasis-studie","tag-re-model-studie","tag-re-novate-studie","tag-replace-studie","tag-rhythmusstoerungen","tag-rivaroxaban","tag-sportif-iii-und-v-studie","tag-thromboembolie","tag-thrombose","tag-vorhofflimmern","tag-ximelagatran"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/959","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=959"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/959\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=959"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=959"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=959"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}